抗新型冠状病毒肺炎药物研究进展

抗新型冠状病毒肺炎药物是阻止病毒传播、遏制疫情的有效手段，收集整理了各国科研机构关于治疗COVID-19的药物及相关研究信息，主要包括可能用于治疗COVID-19的化学药、中药和生物药物等的研究情况；综述了瑞德西韦、法维拉韦、氯喹和羟氯喹等化学药及其联合用药的临床试验初步研究，介绍了“金花清感颗粒”、“连花清瘟胶囊/颗粒”、“血必净注射液”、“清肺排毒汤”、“化湿败毒方”、“宣肺败毒方”等中药及其功效，以及生物大分子药物如治愈患者血浆抗体、托珠单抗、干扰素和疫苗研发等情况。今后，仍需不断完善各种药物治疗COVID-19的临床试验，加快疫苗研发等，进一步探讨防治COVID-19的策略，旨在为治疗新型冠状病毒肺炎的药物筛选提供参考。

Research Progress in Anti-COVID-19 Drugs

Antiviral drugs are effective treatments of COVID-19 to control the epidemic by preventing virus spreading. This review summarizes the current status of research and development of COVID-19 treatments around the world， including chemical medicine， traditional Chinese medicine and biological medicine， etc. The review compiles preliminary studies and clinical trial results of chemical drugs such as Remdesivir， Favipiravjr， Chloroquine， Hydroxychloroquine and combined medication. The present review also introduces traditional Chinese medicines such as "Jinhua Qinggan Granule"， "Lianhua Qingwen Capsules/Granule"， "Xuebijing Injection"， "Lungs Detox Soup"， "Hua Shi Bai Du Fang" and "Xuan Fei Bai Du Fang" as well as their effects. In addition， current development of biomacromolecule drugs such as cured patient plasma， Tocilizumab， interferon and vaccines are presented in this paper. In the future， it is still necessary to improve the clinical trials of various drugs for COVID-19 and speed up vaccine development， etc.. Finally， this review investigates the future strategies to prevent and treat COVID-19， hopefully providing reference for the drug screening of COVID-19.